GSK Gets U.S. Approval for Jideytro for Certain Lung Cancers

Dow Jones

07/23

GSK said its Jideytro treatment has been approved by the U.S. Food and Drug Administration, making it the U.K. drug maker's first approved medicine in lung cancer.

Jideytro, or zidesamtinib, is a selective inhibitor for some adult patients with non-small cell lung cancer who previously received a targeted therapy.

The treatment is part of the portfolio GSK acquired in its purchase of Nuvalent earlier this year.

Write to Sarah Sloat at sarah.sloat@wsj.com

(END) Dow Jones Newswires

July 22, 2026 13:03 ET (17:03 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2653176475"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653176475\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653176475?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 01:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653176475","market":"sg","top_or_hot":-1,"title":"GSK Gets U.S. Approval for Jideytro for Certain Lung Cancers","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GSK said its Jideytro treatment has been approved by the U.S. Food and Drug Administration, making it the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drug maker's first approved medicine in lung cancer. \n</p>\n<p>\n   Jideytro, or zidesamtinib, is a selective inhibitor for some adult patients with non-small cell lung cancer who previously received a targeted therapy. \n</p>\n<p>\n  The treatment is part of the portfolio GSK acquired in its purchase of Nuvalent earlier this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Sarah Sloat at sarah.sloat@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2026 13:03 ET (17:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Gets U.S. Approval for Jideytro for Certain Lung Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Gets U.S. Approval for Jideytro for Certain Lung Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-23 01:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GSK said its Jideytro treatment has been approved by the U.S. Food and Drug Administration, making it the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drug maker's first approved medicine in lung cancer. \n</p>\n<p>\n   Jideytro, or zidesamtinib, is a selective inhibitor for some adult patients with non-small cell lung cancer who previously received a targeted therapy. \n</p>\n<p>\n  The treatment is part of the portfolio GSK acquired in its purchase of Nuvalent earlier this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Sarah Sloat at sarah.sloat@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2026 13:03 ET (17:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653176475","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653176475","pubTimestamp":1784739780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"GSK said its Jideytro treatment has been approved by the U.S. Food and Drug Administration, making it the U.K. drug maker's first approved medicine in lung cancer.Jideytro, or zidesamtinib, is a selective inhibitor for some adult patients with non-small cell lung cancer who previously received a targeted therapy.The treatment is part of the portfolio GSK acquired in its purchase of Nuvalent earlier this year.Write to Sarah Sloat at sarah.sloat@wsj.com Dow Jones NewswiresJuly 22, 2026 13:03 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","BK4007":"制药","BK4588":"碎股","GSKH":"GSK plc ADRhedged","GSK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"葛兰素史克获得美国批准 Jideytro 治疗某些肺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"GSK":1.5,"GSK.UK":0.6},"content_text":"GSK said its Jideytro treatment has been approved by the U.S. Food and Drug Administration, making it the U.K. drug maker's first approved medicine in lung cancer. \n\n\n   Jideytro, or zidesamtinib, is a selective inhibitor for some adult patients with non-small cell lung cancer who previously received a targeted therapy. \n\n\n  The treatment is part of the portfolio GSK acquired in its purchase of Nuvalent earlier this year. \n\n\n \n\n\n  Write to Sarah Sloat at sarah.sloat@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 22, 2026 13:03 ET (17:03 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}